Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Multicohort Trial of Zamtocabtagene Autoleucel (Zamto-Cel) in Subjects With Severe Refractory Autoimmune Diseases

NCT06708845 is registered in ClinicalTrials.gov with Miltenyi Biomedicine GmbH as lead sponsor.

NCT NCT06708845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06708845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Multicohort Trial of Zamtocabtagene Autoleucel (Zamto-Cel) in Subjects With Severe Refractory Autoimmune Diseases
Lead sponsor
Miltenyi Biomedicine GmbH
Phase
Phase 1
Overall status
Recruiting
Start date
July 31, 2026
Completion date
July 31, 2028
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis, lupus nephritis, systemic lupus erythematosus, systemic sclerosis (ssc)